Cargando…
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
OBJECTIVES: AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection. METHODS: We undertook a dose-escalating, open-label, randomized-controlled (...
Autores principales: | Khoo, Saye H, Fitzgerald, Richard, Fletcher, Thomas, Ewings, Sean, Jaki, Thomas, Lyon, Rebecca, Downs, Nichola, Walker, Lauren, Tansley-Hancock, Olana, Greenhalf, William, Woods, Christie, Reynolds, Helen, Marwood, Ellice, Mozgunov, Pavel, Adams, Emily, Bullock, Katie, Holman, Wayne, Bula, Marcin D, Gibney, Jennifer L, Saunders, Geoffrey, Corkhill, Andrea, Hale, Colin, Thorne, Kerensa, Chiong, Justin, Condie, Susannah, Pertinez, Henry, Painter, Wendy, Wrixon, Emma, Johnson, Lucy, Yeats, Sara, Mallard, Kim, Radford, Mike, Fines, Keira, Shaw, Victoria, Owen, Andrew, Lalloo, David G, Jacobs, Michael, Griffiths, Gareth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598307/ https://www.ncbi.nlm.nih.gov/pubmed/34450619 http://dx.doi.org/10.1093/jac/dkab318 |
Ejemplares similares
-
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial
por: Griffiths, Gareth, et al.
Publicado: (2020) -
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter
por: Griffiths, Gareth O., et al.
Publicado: (2021) -
A benchmark for dose-finding studies with unknown ordering
por: Mozgunov, Pavel, et al.
Publicado: (2021) -
Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic
por: Ewings, Sean, et al.
Publicado: (2022) -
An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2
por: Walker, Lauren E., et al.
Publicado: (2021)